This NIH HEAL Initiative UG3/UH3 grant funds preclinical and early clinical development of non-addictive small molecule or biologic analgesics to address the opioid crisis. It exists to accelerate translation of novel pain therapeutics that lack abuse liability, with a strong emphasis on mechanistic validation and regulatory-ready data packages.

- Scientific merit and innovation of the proposed target/mechanism (scored 1-9) - Strength of preclinical validation (in vitro, in vivo, pharmacokinetics, safety) - Feasibility of the development plan and milestones (UG3 phase: target identification to IND-enabling; UH3 phase: Phase I/II trials) - Expertise of the PI and team (must include US-based institution as applicant) - Potential for non-addictive profile and impact on pain management - Letters of support from collaborators and consultants - Budget justification and resource sharing plan

Past awardees include academic-industry partnerships (e.g., Yale, UCSF, Pfizer) developing novel ion channel modulators, biased opioid agonists, and gene therapy approaches. Typical PIs are tenured professors at US research universities with strong translational pharmacology labs. No named examples found on the page, but HEAL-funded projects often feature multi-PI teams with expertise in medicinal chemistry, behavioral pharmacology, and clinical trial design.

A US-based academic PI (PhD or MD) with a track record in analgesic drug discovery, a validated non-opioid target, and preliminary in vivo efficacy data. The ideal applicant has a small molecule lead series with ADMET optimization underway, strong letters from CROs or pharma partners, and a clear regulatory path to IND.